ArticleNature communications2016
Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Colonic neoplasia and celiac disease: A systematic review.World journal of gastroenterology · 2025Pooled it
- Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.Cancer research communications · 2026Article
- Dual pancreatic carcinomas: clonally related or independent primaries?NPJ precision oncology · 2026Article
- Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers.Cancer research and treatment · 2026Article
- Epidemiology of bacterial biofilms on polyps and normal tissues in a screening colonoscopy cohort.Gut microbes · 2025Observational
- Functional Profiling ofCirculation. Genomic and precision medicine · 2025Article
- A 14-Gene Panel for Predicting Colorectal Cancer Recurrence Using Circulating Tumor DNA in Different Testing Conditions.Cancer science · 2025Article
- RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Nature communications · 2024Article
- Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature.Journal of gastrointestinal oncology · 2024Article
- Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.Journal of translational medicine · 2024Article
- Molecular Tumor Testing on Colorectal Adenocarcinoma Specimens in a Large Community-Based Healthcare System.Journal of patient-centered research and reviews · 2024Article
- Impaired neutrophil-mediated cell death drives Ewing's Sarcoma in the background of Down syndrome.Frontiers in oncology · 2024Article
- Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome.Cell reports. Medicine · 2023Article
- Review
- Bioinformatics Analysis of the Prognostic Significance of CAND1 in ERα-Positive Breast Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- FOXA1 regulates alternative splicing in prostate cancer.Cell reports · 2022Article
- Bioinformatics Identification of TUBB as Potential Prognostic Biomarker for Worse Prognosis in ERα-Positive and Better Prognosis in ERα-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors.NPJ precision oncology · 2022Article
- Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database.BMC cancer · 2022Article
- Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synchronous colorectal cancers (syCRCs) are physically separated tumours that develop simultaneously. To understand how the genetic and environmental background influences the development of multiple tumours, here we conduct a comparative analysis of 20 syCRCs from 10 patients. We show that syCRCs have independent genetic origins, acquire dissimilar somatic alterations, and have different clone composition. This inter- and intratumour heterogeneity must be considered in the selection of therapy and in the monitoring of resistance. SyCRC patients show a higher occurrence of inherited damaging mutations in immune-related genes compared to patients with solitary colorectal cancer and to healthy individuals from the 1,000 Genomes Project. Moreover, they have a different composition of immune cell populations in tumour and normal mucosa, and transcriptional differences in immune-related biological processes. This suggests an environmental field effect that promotes multiple tumours likely in the background of inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.